The end of the six-month transition period and the final implementation period of Guangdong's "two vote system"

[policies and regulations of China Pharmaceutical network] there are new actions in Guangdong's two vote system! Recently, Guangdong's drug delivery platform issued the notice on doing a good job in the "two vote system" related work of drug transactions in medical institutions in Guangdong Province (hereinafter referred to as the "notice"), and after a six-month transition period, Guangdong's "two vote system" finally entered the implementation period substantially In the past "multi ticket system" environment, drug prices were pushed up step by step from production to sales through multi-level resellers' transfer and multiple invocations The "two ticket system" is relative to the "multi ticket system", which means that the pharmaceutical production enterprises issue one invoice to the distribution enterprises and the distribution enterprises issue one invoice to the medical institutions The implementation of the "two ticket system" can effectively reduce the circulation of drugs from the pharmaceutical factory to the hospital, not only improve the efficiency and ensure the safety of drug use, but also be conducive to the government's supervision of drugs In addition, the "two ticket system" can prevent some illegal dealers from using some fake drugs and secondary drugs to compete at low prices and crack down on regular drug factories "After the implementation of the" two vote system ", there must be a great adjustment in the original business structure and the selection of distribution enterprises, but in the long run, the benefits are still great," said a pharmaceutical company In the process of greatly shortening the circulation of drugs and standardizing the order of drug circulation, the progress of "two vote system" in Guangdong also combats the irregular behaviors such as "ticket walking and money laundering" in drug circulation Specifically, the pharmaceutical market in Guangdong Province is huge In 2016, the sales scale of the pharmaceutical circulation industry was 160.303 billion yuan, accounting for 8.72% of the total sales of the country, ranking first in the country The compound growth rate in the past five years was 17.17%, which is also higher than the same period of the country Not only that, Guangdong Province is also the "one" of "two vote system", the insiders said: "the implementation of" two vote system "in Guangdong Province has a milestone significance for the reform of China's pharmaceutical circulation market." The author understands that before the "two vote system" is fully implemented in Guangdong Province, there has been a transition period of half a year However, it is expected that the formal implementation will still bring a certain impact on the provincial market However, for enterprises that are not adjusted smoothly, there is likely to be large fluctuations in performance In addition, according to the implementation plan previously announced by Guangdong Province, the transfer of drugs between the drug distribution group enterprises and wholly-owned (holding) subsidiaries may not be regarded as "one vote", but more than one invoice is allowed; As for the distribution of drugs by the grass-roots medical and health institutions (excluding the urban health service center) which meet the conditions of special remoteness and inconvenient transportation, drug distribution enterprises are allowed to issue another purchase and sale invoice on the basis of "two ticket system" The notice also shows a list of 249 varieties that do not implement the "two vote system", mainly including narcotic drugs, psychotropic drugs, radioactive drugs for medical use and toxic drugs for medical use under special management of the state Experts believe that the implementation of the "two vote system" will indeed accelerate the reshuffle of the pharmaceutical industry, but it has little impact on hospitals and consumers The promotion of Guangdong's "two vote system" will undoubtedly accelerate the standardized development of China's pharmaceutical industry After the implementation of the two vote system, the pharmaceutical enterprises benefit from the improvement of industry concentration As they usher in the growth of sales revenue, the sales expenses have also increased significantly, and the proportion in the revenue has been increased According to incomplete statistics, 139 pharmaceutical listed companies have disclosed their 2017 annual reports, and the sales expenses of 123 companies have increased compared with last year At the same time, the revenue of these enterprises has also increased in varying degrees, and the growth rate of the industry is obvious For example, in 2017, the main business income of Pharmaceutical Enterprises above Designated Size in China's pharmaceutical industry was 2982.6 billion yuan, an increase of 12.2% year-on-year, returning to double-digit growth.